The RANGER II superficial femoral artery trial: 1-year results of the long lesion cohort.

ABSTRACT:

Background

The objective of the RANGER II SFA long lesion cohort analysis was to evaluate the safety and effectiveness of the Ranger drug-coated balloon (DCB) in patients with lesion lengths greater than 100 mm.

Methods

Patients from the RANGER II SFA randomized controlled trial and long balloon sub-study were included in the long lesion cohort if their baseline lesion measurement was > 100 mm and if they had been treated with a RANGER DCB. Patients had symptomatic lower limb peripheral artery disease and Rutherford classification 2-4 symptomatology. The endpoints of interest included the 12-month target lesion primary patency and freedom from major adverse events (MAEs).Additional patient outcomes including changes in Rutherford classification were also evaluated.

Result

SUBMITTER: Schroe H 

PROVIDER: S-EPMC9551318 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature